Skip to main content
Caplight Logo









Helex

Helex

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.helex.bio/

Last Round

Seed

Oct 30, 2025

Total Funding Raised

$8.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Helex is a biotechnology company developing genomic medicines for high-burden kidney diseases using proprietary lipid nanoparticle delivery and AI-driven drug design platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Biotech Equipment, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

genomic diagnosticsbioinformatics softwareprecision medicinedrug discoverygene editingmolecular diagnosticsguide-RNA designtherapeutic designpreclinical researchbiotech R&DLNP deliverygenomic data analysisin silico drug designAI-driven drug discoverybiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Helex Comparables

Compare Helex with similar companies based on industry and business-model similarity.

Helex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Illumina, Inc.
62%
Thermo Fisher Scientific Inc.
61%
LatchBio
59%

Helex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 30, 2025
AcceleratorJan 27, 2022
AcceleratorOct 1, 2021

Key People

Founding team and executive leadership

Anirudh Nishtala

Chief Operating Officer

Executive Team

Helex Investors

Notable investors and investment history

Helex investors
InvestorRounds
pi VenturesSeed
IndieBioAccelerator
Bluehill CapitalSeed
SOSVSeed, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    Grew 16% QoQ, from 32 to 37 employees.

  • Jul 27, 2026

    Monthly visitors increased 55% MoM.

Helex Filings

Explore SEC and related filing metadata, where available.

Helex filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Helex's valuation, stock price, and market status.

Is Helex a public or private company?

Helex is a private company.

What is the current stock price of Helex?

Helex is a private company with no public stock price. No recent secondary market data is available.

How much is Helex worth (valuation)?

Valuation information for Helex is not publicly available.

Can I buy Helex stock?

Helex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Helex's last funding round?

Helex's most recent funding round was Seed on October 30, 2025.

Who are the main investors in Helex?

Key investors in Helex include pi Ventures.

Will Helex IPO soon?

No public IPO plans have been announced for Helex.

How can I track Helex secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Helex's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range18
Year Founded2021
Last FundingOct 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?